Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy
Parker Institute for Cancer Immunotherapy · Stanford University · +11 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
240
total citations
- FWCI
- 22.46
- Percentile
- 100%
- References
- 76
Citations per year
Authors
30Topics & keywords
Topics
Keywords
- Chimeric antigen receptor
- Medicine
- Neurotoxicity
- Immunology
- CD19
- Population
- Cell therapy
- Antigen
No related works found for this paper.
Funding
- AAAmerican Association for Cancer Research
- CICalifornia Institute for Regenerative Medicine
- BSBristol-Myers Squibb
- GSGilead Sciences
- VAVirginia and D.K. Ludwig Fund for Cancer Research
- CCelgene
- EIEntertainment Industry Foundation
- PIParker Institute for Cancer Immunotherapy
- ABAdaptive Biotechnologies
- NINational Institutes of HealthAwards: U54-CA209971, 2P01CA049605, 5P30CA124435, S10OD018220
- GGenentech
- KPKite Pharma
- PPharmacyclics
- JTJuno Therapeutics
- NCNational Cancer InstituteAwards: 5P30CA124435, U54-CA209971, CA209971
- JPJanssen Pharmaceuticals
- SCStanford Cancer Institute